Olema Pharmaceuticals (OLMA) Profit After Tax (2020 - 2026)

Olema Pharmaceuticals (OLMA) has reported Profit After Tax for 7 consecutive years, with -$53.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 74.7% year-over-year to -$53.1 million; the TTM figure through Mar 2026 stood at -$185.3 million (down 43.61% YoY), while the FY2025 annual figure was -$162.5 million, down 25.47% from the prior year.
• Profit After Tax declined to -$53.1 million in Q1 2026 per OLMA's latest filing, from -$46.1 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$20.1 million in Q2 2023 and bottomed at -$53.1 million in Q1 2026.
• Historically, Profit After Tax has averaged -$32.3 million across 5 years, with a median of -$30.5 million in 2024.
• Annual changes were most pronounced in 2022 — Profit After Tax plunged 104.99% — and 2023, when it surged 40.25%.
• Olema Pharmaceuticals' Profit After Tax stood at -$25.3 million in 2022, then decreased by 5.74% to -$26.8 million in 2023, then declined by 25.38% to -$33.6 million in 2024, then sank by 37.22% to -$46.1 million in 2025, then slipped by 15.26% to -$53.1 million in 2026.
• Business Quant data shows OLMA's Profit After Tax at -$53.1 million in Q1 2026, -$46.1 million in Q4 2025, and -$42.2 million in Q3 2025.